Pfizer pumps $120M investment into Kalamazoo plant for Paxlovid production

2022-06-06

疫苗

As Pfizer is continuing to double down on its Paxlovid efforts, more room at its facility in Michigan will now be required. The pharma will be committing $120 million to its 1,300-acre facility manufacturing facility in Kalamazoo, MI to enable US-based production in support of its Covid-19 oral antiviral. According to the pharmaceutical giant, the investment will expand the production of the API and RSMs used in the manufacture of nirmatrelvir, a key component in Paxlovid. The company expects the expansion will create more than 250 additional jobs at the Kalamazoo site. “Pfizer Global Supply has made the impossible possible, making billions of vaccine doses and now millions of treatment courses to help battle the deadly Covid-19 pandemic. By increasing production at our Michigan facility, we are both helping patients around the world and expanding important manufacturing innovation to the US,” Pfizer CEO Albert Bourla said in a statement. To produce the antiviral, a significant amount of manufacturing capacity will be needed across all aspects of production. To date, Pfizer has shipped 12 million courses of the drug across 37 countries, including 5 million courses shipped to the US — and manufacturing almost 17 million treatment courses total. Further information on the size and timeline of the expansion was not immediately available to Endpoints News. The company also plans to expand its Modular Aseptic Processing sterile injectable pharmaceutical production facility in Kalamazoo with a phase two investment as well. In 2021, Pfizer broke initial ground on a 420,000 square-foot sterile injectables plant that the drugmaker estimated will bring around 450 new jobs to the region. Pfizer’s plan to expand the facility was initially reported by Michigan-based news site MLive in May. This expansion comes at a time when companies are looking to step up their Covid antiviral game. Thermo Fisher subsidiary Patheon Pharmaceuticals submitted a notification of proposed production activity in May to the FTZ Board for its facilities in Cincinnati. The document stated that the proposed finished products include the active ingredient for Pfizer’s and Merck’s Covid-19 pills, as well as the insomnia treatment Suvorexant. For Pfizer, this comes at a time when it is not only looking to expand the antiviral’s access to the rest of the globe, but Paxlovid has been seeing a significant spike in usage across the country.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构